New screening method may detect twice as many cases of ovarian cancer
the ONA take:
According to a new study published in the Journal of Clinical Oncology, researchers from University College London have developed a new screening tool that can detect twice as many women with ovarian cancer as standard approaches.
Specifically, the study showed that the new method, which detects changes in CA125 levels, could detect cancer in 86% of women with invasive epithelial ovarian cancer.
CA125 is a protein biomarker in the blood of women that has been linked to ovarian cancer. A statistical test then predicts the woman's risk of having ovarian cancer.
"CA125 as a biological marker for ovarian cancer has been called into question. Our findings indicate that this can be an accurate and sensitive screening tool, when used in the context of a woman's pattern of CA125 over time," said Professor Ian Jacobs, chief investigator of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), an co-inventor of the statistical approach.
"What's normal for one woman may not be so for another. It is the change in levels of this protein that's important. My hope is that when the results of UKCTOCS are available this approach will prove capable of detecting ovarian cancer early enough to save lives."
The study evaluated 46,237 women who were screened annually for ovarian cancer over a 14-year period.
A new screening tool can detect twice as many women with ovarian cancer as standard approaches.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|